<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02077803</url>
  </required_header>
  <id_info>
    <org_study_id>CR103257</org_study_id>
    <secondary_id>28431754DIA1062</secondary_id>
    <nct_id>NCT02077803</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants</brief_title>
  <official_title>A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin XR Tablet (4 x 500 mg) in Healthy Fed Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the bioequivalence (similarity of the drug amount in&#xD;
      blood among the formulations) of the fixed dose combination (two components combined in one&#xD;
      tablet) of canagliflozin and metformin extended release (XR) tablet (dose of 2 X 50 mg/1000&#xD;
      mg) with respect to the individual components of canagliflozin (1 x 100 mg) and metformin XR&#xD;
      tablet (4 x 500 mg) in healthy fed participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (the study medication is assigned by chance), open-label (physicians and&#xD;
      participants know the identity of the assigned treatment), single-center, single-dose,&#xD;
      3-treatment, 3-way crossover (the same medications provided to all participants but in&#xD;
      different sequence) study of Fixed Dose Combination (FDC) tablets of canagliflozin (CANA) and&#xD;
      metformin extended release (MET XR) in comparison with tablets of individual components. Two&#xD;
      Fixed Dose Combinations (FDCs) will be evaluated during the study (two types of tablets). The&#xD;
      tablets will be of the same strength (50 mg CANA/1,000 mg MET XR) and will be compared with&#xD;
      equal doses of the individual drugs: canagliflozin (1 x 100 mg tablet) and metformin XR (4 x&#xD;
      500 mg tablets). Thus, there will be 3 treatment periods in the study: Treatment A:&#xD;
      &quot;Reference&quot; treatment of individual components. Treatment B: CANA/MET XR FDC, formulation 1;&#xD;
      and Treatment C: CANA/MET XR FDC, formulation 2. Approximately 42 healthy adult participants&#xD;
      will be randomly assigned to 1 of 3 treatments groups, and then each group will receive all&#xD;
      three treatments in different sequences (3-way crossover). The study will consist of 3&#xD;
      phases: a Screening Phase of approximately 3 weeks (Days -22 to -2), an Open-Label Treatment&#xD;
      Phase consisting of 3 single-dose Treatment Periods of 5 days each (Days -1 through 4)&#xD;
      separated by a washout of 10 to 14 days between Day 1 of each Treatment Period, and a&#xD;
      Follow-up Phase occurring 7 to 10 days after the last study-related procedure on Day 4 of&#xD;
      Treatment Period 3. The total duration of the study will be about 70 days for each&#xD;
      participant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of canagliflozin following the single dose of drug administration</measure>
    <time_frame>Day 1 to Day 2 (predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours postdose); Day 3 (48 hour); and Day 4</time_frame>
    <description>Plasma concentrations of canagliflozin are used to evaluate how long canagliflozin stays in the body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of metformin following the single dose of drug administration</measure>
    <time_frame>Day 1 to Day 2 (predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, and 30 hours postdose); and Day 3 (36 hours)</time_frame>
    <description>Plasma concentrations of metformin are used to evaluate how long it stays in the body.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to Day 10 of the follow-up period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 100 mg, and 4 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin, 100 mg</intervention_name>
    <description>Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin XR, 500 mg</intervention_name>
    <description>Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg</intervention_name>
    <description>Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 1, to be taken orally.</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg</intervention_name>
    <description>Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 2, to be taken orally.</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must sign an informed consent document indicating they understand the purpose of the&#xD;
             study and procedures&#xD;
&#xD;
          -  Must have a body mass index (BMI) of between 18 and 30 kg/m², inclusive&#xD;
&#xD;
          -  Must have a body weight of not less than 50 kg&#xD;
&#xD;
          -  Must have a blood pressure between 90 and 140 mmHg inclusive, systolic, and no higher&#xD;
             than 90 mmHg diastolic at screening&#xD;
&#xD;
          -  Must have normal renal function and no evidence of kidney damage (including&#xD;
             abnormalities in blood or urine tests)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of or current clinically significant medical illness&#xD;
&#xD;
          -  Use of any prescription or nonprescription medication (including vitamins and herbal&#xD;
             supplements)&#xD;
&#xD;
          -  History of clinically significant allergies, especially known hypersensitivity or&#xD;
             intolerance to drugs or lactose&#xD;
&#xD;
          -  Known allergy to heparin or history of heparin induced thrombocytopenia&#xD;
&#xD;
          -  Donated blood or blood products or had substantial loss of blood within 3 months&#xD;
             before screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>February 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>September 2, 2014</last_update_submitted>
  <last_update_submitted_qc>September 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Canagliflozin</keyword>
  <keyword>Metformin</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>GLUMETZA®</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

